AnaptysBio (ANAB), a clinical stage biotech focused on immunology therapeutics, continues to attract attention as investors weigh its recent share performance, clinical pipeline progress and current valuation at a market cap of about US$1.73b.

At a share price of US$58.48, AnaptysBio has seen its short term share price return slip over the past quarter. Its year to date share price return of 30.10% and very large 1 year total shareholder return suggest earlier momentum remains a key part of the story.

If recent biotech gains have you looking further across the sector, this is a good moment to scan a curated list of 38 healthcare AI stocks

With AnaptysBio trading at US$58.48 and indicators like an intrinsic discount and a gap to analyst targets in play, you have to ask: is there still mispricing here, or is the market already baking in future growth?

Preferred Price-to-Sales Multiple of 7.3x: Is It Justified?

On the numbers provided, AnaptysBio trades on a P/S ratio of 7.3x, which, at a last close of $58.48, places it well below several reference points for its peers and the broader US biotechs sector.

The P/S ratio compares the company’s market value with its annual revenue and is often used for biotechs that are not yet profitable, as is the case with AnaptysBio, which currently reports a net loss of $26.79m on revenue of $232.39m. For a clinical stage biotech with multiple programs in trials and no sustained profits yet, investors are essentially weighing pipeline potential and expected future revenue against today’s sales base.

Relative to the US Biotechs industry average P/S of 11.1x and a peer group average of 30.2x, AnaptysBio’s 7.3x ratio sits at a clear discount, indicating the stock is priced lower per dollar of sales than many peers. However, when compared to an estimated fair P/S ratio of 4.5x, the current multiple looks high relative to that statistical benchmark and could represent a level the market might move toward if sentiment or expectations change.

Result: Price-to-sales of 7.3x (UNDERVALUED compared to peers but ABOVE estimated fair ratio)

However, the AnaptysBio narrative still hinges on successful trial outcomes and collaboration milestones. Any setback or delay could quickly challenge today’s valuation gap story.

Another View on AnaptysBio: What Does the DCF Say?

The SWS DCF model presents a very different picture for AnaptysBio. With the stock at $58.48 and an estimated future cash flow value of $349.73, this approach suggests the shares are trading at a steep discount. If that gap persists, is the market missing something or are the assumptions too generous?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AnaptysBio for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With both optimism and caution running through the AnaptysBio story, this is the moment to review the figures yourself and decide how the risk reward trade off stacks up for your portfolio by weighing 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond AnaptysBio?

If AnaptysBio has sharpened your interest, do not stop here. Use the Simply Wall Street Screener to uncover fresh opportunities that could suit your next move.

• Spot potential bargains early by scanning 44 high quality undervalued stocks that combine quality fundamentals with pricing that may appeal to value focused investors.
• Prioritise resilience by checking 69 resilient stocks with low risk scores that stand out for steadier risk profiles when you want fewer surprises in your portfolio.
• Get ahead of the crowd with the screener containing 18 high quality undiscovered gems that have solid foundations but remain off many investors’ radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.